FDA Finalizes ODT Guidance, Sticks To More Restrictive Recommendations
Executive Summary
FDA drew a line in the sand in finalizing a guidance limiting orally disintegrating tablets to a 30-second dissolution time and 500 mg weight, despite industry arguments that such restrictions would discourage development of ODTs
You may also be interested in...
Generic Approval Standards For Vancomycin Tightened In FDA Draft Guidance
FDA has tightened approval standards for generic oral vancomycin, but appears to have left enough latitude in bioequivalence testing requirements to not greatly impede generic competition
Generics Avoid Many, Not All, Disclosure Requirements For ClinicalTrials.gov
Generic firms appear to have avoided most, but not all, of the reporting requirements for ClinicalTrials.gov, though winning complete privacy protections appears as though it will require congressional intervention
Generics Avoid Many, Not All, Disclosure Requirements For ClinicalTrials.gov
Generic firms appear to have avoided most, but not all, of the reporting requirements for ClinicalTrials.gov, though winning complete privacy protections appears as though it will require congressional intervention